Treace Medical Concepts Inc (TMCI) - Net Assets
Based on the latest financial reports, Treace Medical Concepts Inc (TMCI) has net assets worth $89.19 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($196.59 Million) and total liabilities ($107.40 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Treace Medical Concepts Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $89.19 Million |
| % of Total Assets | 45.37% |
| Annual Growth Rate | 104.38% |
| 5-Year Change | 14447.94% |
| 10-Year Change | N/A |
| Growth Volatility | 4758.14 |
Treace Medical Concepts Inc - Net Assets Trend (2019–2024)
This chart illustrates how Treace Medical Concepts Inc's net assets have evolved over time, based on quarterly financial data. Also explore TMCI total assets for the complete picture of this company's asset base.
Annual Net Assets for Treace Medical Concepts Inc (2019–2024)
The table below shows the annual net assets of Treace Medical Concepts Inc from 2019 to 2024. For live valuation and market cap data, see Treace Medical Concepts Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $112.89 Million | -18.16% |
| 2023-12-31 | $137.94 Million | +127.89% |
| 2022-12-31 | $60.53 Million | -34.97% |
| 2021-12-31 | $93.07 Million | +11893.94% |
| 2020-12-31 | $776.00K | -75.45% |
| 2019-12-31 | $3.16 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Treace Medical Concepts Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17230400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $62.00K | 0.05% |
| Other Comprehensive Income | $97.00K | 0.09% |
| Other Components | $302.72 Million | 268.15% |
| Total Equity | $112.89 Million | 100.00% |
Treace Medical Concepts Inc Competitors by Market Cap
The table below lists competitors of Treace Medical Concepts Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Averlogic Technologies
TWO:6198
|
$118.53 Million |
|
Lam Soon (Thailand) Public Company Limited
BK:LST
|
$118.59 Million |
|
Yibitas Yozgat Isci Birligi Insaat Malzemeleri Ticaret Sanayi AS
IS:YBTAS
|
$118.59 Million |
|
RTX A/S
CO:RTX
|
$118.60 Million |
|
Forrester Research Inc
NASDAQ:FORR
|
$118.51 Million |
|
Roto Pumps Limited
NSE:ROTO
|
$118.49 Million |
|
Smith & Nephew PLC
LSE:SN
|
$118.48 Million |
|
Diamond Building Products Public Company Limited
BK:DRT
|
$118.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Treace Medical Concepts Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 137,938,000 to 112,892,000, a change of -25,046,000 (-18.2%).
- Net loss of 55,743,000 reduced equity.
- Other comprehensive income decreased equity by 66,000.
- Other factors increased equity by 30,763,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-55.74 Million | -49.38% |
| Other Comprehensive Income | $-66.00K | -0.06% |
| Other Changes | $30.76 Million | +27.25% |
| Total Change | $- | -18.16% |
Book Value vs Market Value Analysis
This analysis compares Treace Medical Concepts Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.02x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 30.11x to 1.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.06 | $1.86 | x |
| 2020-12-31 | $0.02 | $1.86 | x |
| 2021-12-31 | $1.72 | $1.86 | x |
| 2022-12-31 | $1.10 | $1.86 | x |
| 2023-12-31 | $2.27 | $1.86 | x |
| 2024-12-31 | $1.82 | $1.86 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Treace Medical Concepts Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -49.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -26.63%
- • Asset Turnover: 0.96x
- • Equity Multiplier: 1.92x
- Recent ROE (-49.38%) is above the historical average (-130.95%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -134.93% | -10.82% | 1.33x | 9.40x | $-4.58 Million |
| 2020 | -472.68% | -6.39% | 1.37x | 53.88x | $-3.75 Million |
| 2021 | -22.08% | -21.77% | 0.67x | 1.51x | $-29.86 Million |
| 2022 | -70.73% | -30.19% | 0.89x | 2.63x | $-48.87 Million |
| 2023 | -35.91% | -26.47% | 0.74x | 1.83x | $-63.32 Million |
| 2024 | -49.38% | -26.63% | 0.96x | 1.92x | $-67.03 Million |
Industry Comparison
This section compares Treace Medical Concepts Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Treace Medical Concepts Inc (TMCI) | $89.19 Million | -134.93% | 1.20x | $118.52 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About Treace Medical Concepts Inc
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to correct three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. It also provides Lap… Read more